WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting

Capital Markets

Open PDF
  • A Leader in IPOs

    Wilson Sonsini is the established leader in the U.S. IPO market. The firm has represented some of the world’s most iconic companies in connection with high-value IPOs, including Google, LinkedIn, Lyft, and Square.

  • Ranked Among the Top Advisors to Companies and Underwriters

    We are consistently ranked by Bloomberg, LSEG, and CapitalIQ as a leading advisor to companies and underwriters based on the number of completed IPOs and equity and equity-linked offerings.

  • A Leading Advisor to International Clients

    The firm has substantial experience advising non-U.S. companies and investment banks on U.S. and Hong Kong IPOs and other capital markets transactions. 

Why Wilson Sonsini?

Unparalleled Experience

As the recognized IPO leader and with over 300 public company clients, Wilson Sonsini combines a unique depth of perspective with a pragmatic, business-oriented style to address all the needs of public companies and private companies that aspire to be public.

Recognized Leader in Addressing All Needs of the Enterprise

  • Named a "Corporate–On the Radar" winner, which honors the top go-to firms representing tech sector clients, in the 2022 California Leaders in Tech Law and Innovation Awards – The Recorder 
  • Ranked among the top firms worldwide, based on the number of M&A deals, in quarterly and year-end rankings – LSEG
  • Ranked as the No. 1 law firm in the U.S. and globally based on the number of company-side venture financing rounds raised for clients in 2025 – LSEG

Balanced Company and Underwriter-Side Practice

Wilson Sonsini has deep experience serving underwriters in connection with a wide variety of high-profile, complex, and precedent-setting capital markets transactions. Some of our investment bank clients include BofA Securities, Citigroup, Credit Suisse, Deutsche Bank, Goldman Sachs, J.P. Morgan, and Morgan Stanley.

Overview

Why Wilson Sonsini?

Unparalleled Experience

As the recognized IPO leader and with over 300 public company clients, Wilson Sonsini combines a unique depth of perspective with a pragmatic, business-oriented style to address all the needs of public companies and private companies that aspire to be public.

Recognized Leader in Addressing All Needs of the Enterprise

  • Named a "Corporate–On the Radar" winner, which honors the top go-to firms representing tech sector clients, in the 2022 California Leaders in Tech Law and Innovation Awards – The Recorder 
  • Ranked among the top firms worldwide, based on the number of M&A deals, in quarterly and year-end rankings – LSEG
  • Ranked as the No. 1 law firm in the U.S. and globally based on the number of company-side venture financing rounds raised for clients in 2025 – LSEG

Balanced Company and Underwriter-Side Practice

Wilson Sonsini has deep experience serving underwriters in connection with a wide variety of high-profile, complex, and precedent-setting capital markets transactions. Some of our investment bank clients include BofA Securities, Citigroup, Credit Suisse, Deutsche Bank, Goldman Sachs, J.P. Morgan, and Morgan Stanley.

Client Highlights
Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On Offering
On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.
Alerts
SEC Proposes Significant Registered Offering Reforms to Increase Public Market Access
On May 19, 2026, the U.S. Securities and Exchange Commission (the SEC or Commission) announced proposed rule and form amendments that would substantially revise the framework for registered securities offerings by U.S. public companies. The proposal is intended to facilitate capital formation by broadening access to short-form registration, expanding offering communications flexibility, and reducing certain procedural burdens associated with registered offerings, while maintaining robust investor protections.
Alerts
SEC Proposes Streamlining Filer Status Framework and Broadening Availability of Scaled Disclosures
On May 19, 2026, the U.S. Securities and Exchange Commission (the SEC or Commission) announced proposed rule and form amendments that would streamline the existing filer status framework and extend many of today’s scaled disclosure requirements and accommodations to a significantly larger portion of reporting companies. The proposal is intended to better align disclosure and compliance obligations with issuer size and maturity while preserving core investor protections. The Commission estimates that approximately 81 percent of reporting companies would qualify for scaled disclosure under the proposal, although large accelerated filers would continue to represent the majority of the U.S. equity market capitalization.
Blog Posts
SEC Chairman Invites Comment on Modernizing the IPO Process
In remarks delivered on May 26, 2026, at the Stanford Rock Center for Corporate Governance, SEC Chairman Paul S. Atkins expressly invited public input on how the Commission should improve and modernize the IPO process. The remarks indicate that the Commission is prepared to consider whether long-standing rules governing offering communications, routes to the public markets, and disclosure obligations continue to serve capital formation efficiently in the current market environment. The SEC has provided an online form for submission of comments, and Chairman Atkins requested that any comments be submitted by July 27, 2026.
Client Highlights
Wilson Sonsini Advises WuXi AppTec on Issuance of RMB6,780 Million USD Settled Zero Coupon Convertible Bonds Due 2027
On May 21, 2026, all the conditions precedent under the subscription agreement dated May 14, 2024, entered into between WuXi AppTec Co., Ltd. (WuXi AppTec), Morgan Stanley Asia Limited, Citigroup Global Markets Limited, and Goldman Sachs (Asia) L.L.C. have been fulfilled and the issuance of the RMB6,780 million USD settled zero coupon convertible bonds due 2027 (the Bonds) in an aggregate principal amount of RMB6,780 million was completed. The net proceeds from the subscription of the Bonds, after deducting the managers’ commissions and expenses in connection with the offering, will be approximately US$1,023 million, and will be utilized in the following manner: (a) approximately 90 percent will be used for global capacity and capability expansion and (b) approximately 10 percent will be used for general corporate purposes. A formal application has been made to the Vienna Stock Exchange for the listing of the Bonds on the Vienna Stock Exchange.
Blog Posts
SEC Proposes Significant Reforms to Filer Status and Registered Offering Frameworks
On May 19, 2026, the SEC proposed two significant rulemakings: 1) Enhancement of Emerging Growth Company Accommodations and Simplification of Filer Status for Reporting Companies and 2) Registered Offering Reform. This blog post summarizes aspects of each proposal.
View All
Insights
Client Highlights
Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On Offering
On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.
Alerts
SEC Proposes Significant Registered Offering Reforms to Increase Public Market Access
On May 19, 2026, the U.S. Securities and Exchange Commission (the SEC or Commission) announced proposed rule and form amendments that would substantially revise the framework for registered securities offerings by U.S. public companies. The proposal is intended to facilitate capital formation by broadening access to short-form registration, expanding offering communications flexibility, and reducing certain procedural burdens associated with registered offerings, while maintaining robust investor protections.
Alerts
SEC Proposes Streamlining Filer Status Framework and Broadening Availability of Scaled Disclosures
On May 19, 2026, the U.S. Securities and Exchange Commission (the SEC or Commission) announced proposed rule and form amendments that would streamline the existing filer status framework and extend many of today’s scaled disclosure requirements and accommodations to a significantly larger portion of reporting companies. The proposal is intended to better align disclosure and compliance obligations with issuer size and maturity while preserving core investor protections. The Commission estimates that approximately 81 percent of reporting companies would qualify for scaled disclosure under the proposal, although large accelerated filers would continue to represent the majority of the U.S. equity market capitalization.
Blog Posts
SEC Chairman Invites Comment on Modernizing the IPO Process
In remarks delivered on May 26, 2026, at the Stanford Rock Center for Corporate Governance, SEC Chairman Paul S. Atkins expressly invited public input on how the Commission should improve and modernize the IPO process. The remarks indicate that the Commission is prepared to consider whether long-standing rules governing offering communications, routes to the public markets, and disclosure obligations continue to serve capital formation efficiently in the current market environment. The SEC has provided an online form for submission of comments, and Chairman Atkins requested that any comments be submitted by July 27, 2026.
Client Highlights
Wilson Sonsini Advises WuXi AppTec on Issuance of RMB6,780 Million USD Settled Zero Coupon Convertible Bonds Due 2027
On May 21, 2026, all the conditions precedent under the subscription agreement dated May 14, 2024, entered into between WuXi AppTec Co., Ltd. (WuXi AppTec), Morgan Stanley Asia Limited, Citigroup Global Markets Limited, and Goldman Sachs (Asia) L.L.C. have been fulfilled and the issuance of the RMB6,780 million USD settled zero coupon convertible bonds due 2027 (the Bonds) in an aggregate principal amount of RMB6,780 million was completed. The net proceeds from the subscription of the Bonds, after deducting the managers’ commissions and expenses in connection with the offering, will be approximately US$1,023 million, and will be utilized in the following manner: (a) approximately 90 percent will be used for global capacity and capability expansion and (b) approximately 10 percent will be used for general corporate purposes. A formal application has been made to the Vienna Stock Exchange for the listing of the Bonds on the Vienna Stock Exchange.
Blog Posts
SEC Proposes Significant Reforms to Filer Status and Registered Offering Frameworks
On May 19, 2026, the SEC proposed two significant rulemakings: 1) Enhancement of Emerging Growth Company Accommodations and Simplification of Filer Status for Reporting Companies and 2) Registered Offering Reform. This blog post summarizes aspects of each proposal.
View All
Affiliated Programs
NASDAQ Spring 2026 IPO Bootcamp
Join us for the second webinar in 2026 Bootcamp series. Hosted by Nasdaq Entrepreneurial Center, this half-day program is designed to help founders, CFOs, and executives be prepared for the complex journey of taking a company public. Speakers from Wilson Sonsini and KPMG will share actionable insights on IPO strategy that attract investors and ensure compliance, SEC regulations, financial reporting, and more.
Affiliated Programs
Circle|Up New York
Wilson Sonsini will join The Circle, Hiive, and Gallagher for Circle|Up NY, an exclusive program for East Coast-based CFO|Circle members. Attendees will enjoy the fireside chat featuring Jeff Hoffmeister, Chief Financial Officer at Shopify and informal networking.
Affiliated Programs
Growth Unlocked: A Roadmap to Transaction Readiness
Wilson Sonsini and Connor Group will co-host “Growth Unlocked” in Utah, an exclusive program designed for senior executives navigating or actively exploring IPO and M&A opportunities.
Affiliated Programs
Circle|Summit 2026
Wilson Sonsini is proud to sponsor The Circle and MUFG’s exclusive leadership retreat, a two-and-a-half day program designed for influential CFOs from growth-stage and newly public companies. 
Affiliated Programs
NASDAQ Fall 2025 IPO Bootcamp
In partnership with the Nasdaq Entrepreneurial Center, KPMG, and Wells Fargo, Wilson Sonsini will co-host the third webinar in the Fall 2025 Bootcamp Series. This exclusive, half-day program is designed to prepare founders, CFOs, and executives for the complex journey of taking a company public.
Affiliated Programs
American Diabetes Association: 30th Annual Leaders Forum HealthTech Showcase
Wilson Sonsini is proud to sponsor the American Diabetes Association Leaders Forum.
View All
Events
Affiliated Programs
NASDAQ Spring 2026 IPO Bootcamp
Join us for the second webinar in 2026 Bootcamp series. Hosted by Nasdaq Entrepreneurial Center, this half-day program is designed to help founders, CFOs, and executives be prepared for the complex journey of taking a company public. Speakers from Wilson Sonsini and KPMG will share actionable insights on IPO strategy that attract investors and ensure compliance, SEC regulations, financial reporting, and more.
Affiliated Programs
Circle|Up New York
Wilson Sonsini will join The Circle, Hiive, and Gallagher for Circle|Up NY, an exclusive program for East Coast-based CFO|Circle members. Attendees will enjoy the fireside chat featuring Jeff Hoffmeister, Chief Financial Officer at Shopify and informal networking.
Affiliated Programs
Growth Unlocked: A Roadmap to Transaction Readiness
Wilson Sonsini and Connor Group will co-host “Growth Unlocked” in Utah, an exclusive program designed for senior executives navigating or actively exploring IPO and M&A opportunities.
Affiliated Programs
Circle|Summit 2026
Wilson Sonsini is proud to sponsor The Circle and MUFG’s exclusive leadership retreat, a two-and-a-half day program designed for influential CFOs from growth-stage and newly public companies. 
Affiliated Programs
NASDAQ Fall 2025 IPO Bootcamp
In partnership with the Nasdaq Entrepreneurial Center, KPMG, and Wells Fargo, Wilson Sonsini will co-host the third webinar in the Fall 2025 Bootcamp Series. This exclusive, half-day program is designed to prepare founders, CFOs, and executives for the complex journey of taking a company public.
Affiliated Programs
American Diabetes Association: 30th Annual Leaders Forum HealthTech Showcase
Wilson Sonsini is proud to sponsor the American Diabetes Association Leaders Forum.
View All
Megan J. Baier
Partner
New York
Megan represents technology and life sciences clients in corporate transactional matters.
  • Corporate
View Profile
Mark Bass
Partner
Washington, D.C.
Mark Bass is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he works with public and private technology companies at all stages of growth. He also represents venture capital funds, private equity firms, and investment banks in financings and public offerings. 
  • Corporate
View Profile
Mark B. Baudler
Partner
Palo Alto
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
  • Corporate
View Profile
Steven V. Bernard
Partner
Palo Alto

Steve has represented non-U.S. and domestic companies in U.S. IPOs, global securities offerings, cross-border M&A, and SEC compliance for more than 25 years.

  • Corporate
View Profile
Ashmi Bhagani
Partner
London
Ashmi Bhagani is a partner in the London office of Wilson Sonsini Goodrich & Rosati, where she has a diverse transatlantic corporate and securities practice focused on the technology and life sciences sectors.
  • Corporate
View Profile
Richard C. Blake
Partner
Palo Alto
Richard has a comprehensive corporate law background, with extensive experience in public offerings.
  • Corporate
View Profile
Tamara Brightwell
Partner
Washington, D.C.
Tamara Brightwell is a corporate partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where she counsels public company clients on a wide range of regulatory matters and provides expert securities law advice on complex capital markets transactions.
  • Corporate
View Profile
Weiheng Chen
Partner
Hong Kong
Weiheng leads Wilson Sonsini's Greater China practice and he focuses on capital markets, M&A, and private equity transactions.
  • Corporate
View Profile
Yang Chu
Partner
Hong Kong
Yang Chu is a corporate partner in the Hong Kong office of Wilson Sonsini Goodrich & Rosati. He has extensive experience advising clients on a broad range of corporate matters, including Hong Kong IPOs and follow-on equity and debt offerings, public and private M&A transactions and privatizations, and pre-IPO and cross-over financings. Yang also counsels Hong Kong-listed companies on post-listing compliance, corporate governance, executive compensation, and related regulatory matters.

Yang’s practice is focused on clients in the healthcare, life sciences, technology, media, consumer, and retail sectors, including corporates and their respective founders, executives, and private equity and venture capital investors.

Prior to joining the firm, Yang was a capital markets partner in the Hong Kong office of another international firm.

Yang is fluent in both Mandarin and English, and is conversational in Cantonese. 
  • Corporate
View Profile
Kenneth A. Clark
Partner
Palo Alto
Ken focuses on life sciences clients and often acts as outside legal counsel to biotechnology companies and their boards.
  • Corporate
View Profile
View All
People
Megan J. Baier
Partner
New York
Megan represents technology and life sciences clients in corporate transactional matters.
  • Corporate
View Profile
Mark Bass
Partner
Washington, D.C.
Mark Bass is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he works with public and private technology companies at all stages of growth. He also represents venture capital funds, private equity firms, and investment banks in financings and public offerings. 
  • Corporate
View Profile
Mark B. Baudler
Partner
Palo Alto
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
  • Corporate
View Profile
Steven V. Bernard
Partner
Palo Alto

Steve has represented non-U.S. and domestic companies in U.S. IPOs, global securities offerings, cross-border M&A, and SEC compliance for more than 25 years.

  • Corporate
View Profile
Ashmi Bhagani
Partner
London
Ashmi Bhagani is a partner in the London office of Wilson Sonsini Goodrich & Rosati, where she has a diverse transatlantic corporate and securities practice focused on the technology and life sciences sectors.
  • Corporate
View Profile
Richard C. Blake
Partner
Palo Alto
Richard has a comprehensive corporate law background, with extensive experience in public offerings.
  • Corporate
View Profile
Tamara Brightwell
Partner
Washington, D.C.
Tamara Brightwell is a corporate partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where she counsels public company clients on a wide range of regulatory matters and provides expert securities law advice on complex capital markets transactions.
  • Corporate
View Profile
Weiheng Chen
Partner
Hong Kong
Weiheng leads Wilson Sonsini's Greater China practice and he focuses on capital markets, M&A, and private equity transactions.
  • Corporate
View Profile
Yang Chu
Partner
Hong Kong
Yang Chu is a corporate partner in the Hong Kong office of Wilson Sonsini Goodrich & Rosati. He has extensive experience advising clients on a broad range of corporate matters, including Hong Kong IPOs and follow-on equity and debt offerings, public and private M&A transactions and privatizations, and pre-IPO and cross-over financings. Yang also counsels Hong Kong-listed companies on post-listing compliance, corporate governance, executive compensation, and related regulatory matters.

Yang’s practice is focused on clients in the healthcare, life sciences, technology, media, consumer, and retail sectors, including corporates and their respective founders, executives, and private equity and venture capital investors.

Prior to joining the firm, Yang was a capital markets partner in the Hong Kong office of another international firm.

Yang is fluent in both Mandarin and English, and is conversational in Cantonese. 
  • Corporate
View Profile
Kenneth A. Clark
Partner
Palo Alto
Ken focuses on life sciences clients and often acts as outside legal counsel to biotechnology companies and their boards.
  • Corporate
View Profile
View All

Equity-Linked and Debt Capital Markets

Deep Experience in Structured and Complex Financing Transactions

Wilson Sonsini has substantial experience in structuring and negotiating the full range of capital markets transactions, including: 

  • Pre-public offerings of equity-linked and debt securities
  • Convertible notes
  • High-yield notes
  • Investment-grade notes
  • Shelf registrations, including wall crossed equity offerings, registered direct offerings, at-the-market offerings, and equity lines
  • Private investment in public equity (PIPE) transactions
  • Other types of structured financial products, including preferred stock, trust preferred, and exchangeable products

Expertise in Stock Buybacks and Exchanges

Wilson Sonsini regularly advises enterprise clients on repurchases of common stock or debt securities, including through privately negotiated repurchases, open market repurchases, and tender offers, as well as restructuring transactions of outstanding securities involving private exchanges or registered exchange offers.

Derivative Transactions

We counsel companies and investment banks on a wide variety of equity derivatives transactions, including:

  • Accelerated stock repurchases (including minimum/maximum durations, capped and/or collared)
  • Tax integrated bond hedge and warrant transactions
  • Tax integrated capped call transactions
  • Non-tax integrated capped call transactions
  • Prepaid forward stock purchase contracts to facilitate stock borrow
  • Other types of equity derivative transactions

Wilson Sonsini also advises companies with respect to commercial hedging arrangements, including foreign exchange (deliverable and non-deliverable), interest rate, and commodity derivative transactions. In addition, we assist enterprise clients with Dodd-Frank compliance issues.

Please contact any member of the firm’s Derivatives practice for more information.

Equity-Linked and Debt Capital Markets

Equity-Linked and Debt Capital Markets

Deep Experience in Structured and Complex Financing Transactions

Wilson Sonsini has substantial experience in structuring and negotiating the full range of capital markets transactions, including: 

  • Pre-public offerings of equity-linked and debt securities
  • Convertible notes
  • High-yield notes
  • Investment-grade notes
  • Shelf registrations, including wall crossed equity offerings, registered direct offerings, at-the-market offerings, and equity lines
  • Private investment in public equity (PIPE) transactions
  • Other types of structured financial products, including preferred stock, trust preferred, and exchangeable products

Expertise in Stock Buybacks and Exchanges

Wilson Sonsini regularly advises enterprise clients on repurchases of common stock or debt securities, including through privately negotiated repurchases, open market repurchases, and tender offers, as well as restructuring transactions of outstanding securities involving private exchanges or registered exchange offers.

Derivative Transactions

We counsel companies and investment banks on a wide variety of equity derivatives transactions, including:

  • Accelerated stock repurchases (including minimum/maximum durations, capped and/or collared)
  • Tax integrated bond hedge and warrant transactions
  • Tax integrated capped call transactions
  • Non-tax integrated capped call transactions
  • Prepaid forward stock purchase contracts to facilitate stock borrow
  • Other types of equity derivative transactions

Wilson Sonsini also advises companies with respect to commercial hedging arrangements, including foreign exchange (deliverable and non-deliverable), interest rate, and commodity derivative transactions. In addition, we assist enterprise clients with Dodd-Frank compliance issues.

Please contact any member of the firm’s Derivatives practice for more information.

Global Capital Markets

Broad Global Capital Markets Experience

Wilson Sonsini has substantial experience advising non-U.S. companies and investment banks on IPOs and other capital markets transactions, including:

  • U.S. IPOs by non-U.S. companies
  • Hong Kong IPOs
  • Dual listings and global trading issues for dual-listed companies
  • American Depositary Receipt (ADR) facilities
  • Global stock buybacks
  • SEC reporting by foreign private issuers and deemed domestic issuers
  • Melding the unique aspects of home country corporate law with applicable U.S. securities laws
Global Capital Markets

Global Capital Markets

Broad Global Capital Markets Experience

Wilson Sonsini has substantial experience advising non-U.S. companies and investment banks on IPOs and other capital markets transactions, including:

  • U.S. IPOs by non-U.S. companies
  • Hong Kong IPOs
  • Dual listings and global trading issues for dual-listed companies
  • American Depositary Receipt (ADR) facilities
  • Global stock buybacks
  • SEC reporting by foreign private issuers and deemed domestic issuers
  • Melding the unique aspects of home country corporate law with applicable U.S. securities laws

What Is a Direct Listing?

  • An alternative to a traditional underwritten initial public offering
  • A private company becomes a publicly traded company by listing all of its outstanding shares on the NYSE or Nasdaq
  • Previously, NYSE and Nasdaq only permitted selling shareholder direct listings. Existing shareholders were permitted to sell all or a portion of their shares immediately, but were not obligated to do so. Now, NYSE allows companies to raise primary proceeds through the direct listing process as well (Nasdaq proposals for primary direct listings are pending).
  • The benefits of direct listings include market-driven price discovery, the ability for existing shareholders to sell some or all of their shares on the first day of trading, and trading access to a greater number of market participants. Drawbacks include less control over investors that buy shares and the potential for trading volatility.

Underwritten IPO vs. Direct Listing – Process

Our Capabilities

As our capital markets team has demonstrated in handling other complex and sophisticated transactions—including those that offer the firm’s clients innovative options that are best suited to helping them achieve their unique objectives—our team brings together expertise from a broad range of disciplines. For example, in addition to our nationally recognized Capital Markets practice, we have substantial experience in public company representation, corporate governance, benefits and compensation, and tax. Drawing from that expertise, we can offer comprehensive and coordinated counsel across all areas involved in sophisticated transactions like direct listings.

Our objective is to meet our clients’ needs to pursue increasingly creative and sophisticated transactions that accommodate their going-forward interests. Wilson Sonsini’s stature as a leading corporate transactions practice was largely built on our capacity to adapt to market changes and quickly help our clients seize important business opportunities.

Direct Listings

What Is a Direct Listing?

  • An alternative to a traditional underwritten initial public offering
  • A private company becomes a publicly traded company by listing all of its outstanding shares on the NYSE or Nasdaq
  • Previously, NYSE and Nasdaq only permitted selling shareholder direct listings. Existing shareholders were permitted to sell all or a portion of their shares immediately, but were not obligated to do so. Now, NYSE allows companies to raise primary proceeds through the direct listing process as well (Nasdaq proposals for primary direct listings are pending).
  • The benefits of direct listings include market-driven price discovery, the ability for existing shareholders to sell some or all of their shares on the first day of trading, and trading access to a greater number of market participants. Drawbacks include less control over investors that buy shares and the potential for trading volatility.

Underwritten IPO vs. Direct Listing – Process

Our Capabilities

As our capital markets team has demonstrated in handling other complex and sophisticated transactions—including those that offer the firm’s clients innovative options that are best suited to helping them achieve their unique objectives—our team brings together expertise from a broad range of disciplines. For example, in addition to our nationally recognized Capital Markets practice, we have substantial experience in public company representation, corporate governance, benefits and compensation, and tax. Drawing from that expertise, we can offer comprehensive and coordinated counsel across all areas involved in sophisticated transactions like direct listings.

Our objective is to meet our clients’ needs to pursue increasingly creative and sophisticated transactions that accommodate their going-forward interests. Wilson Sonsini’s stature as a leading corporate transactions practice was largely built on our capacity to adapt to market changes and quickly help our clients seize important business opportunities.

Wilson Sonsini Life Sciences: Technical Writing and IPO Documentation

Wilson Sonsini offers a suite of services for life sciences clients navigating the complexities of initial public offerings (IPOs). Leveraging the scientific expertise of the firm’s Patents and Innovations and Corporate practices, our team provides specialized business and technical writing services, including drafting the business section of the registration statement, preparing investor presentations, and handling other technical writing needed during the IPO process.

Uniquely, our life sciences-focused patent team consists of more than 170 legal professionals with Ph.D.s and other advanced degrees in biology, chemistry, biomedical sciences, or engineering. Our technical writing expertise encompasses biopharmaceuticals, small molecule therapeutics, research tools, medical devices, genomics, bioinformatics, artificial intelligence, and materials. Because our professionals are credentialed scientists who are intimately familiar with the science at the core of the client’s business, as scientific writers, they are well positioned to draft a Form S-1 or Form F-1 business section that meets the SEC’s exacting standards for registration statements, dovetails with the client’s patent strategy, and tells a compelling and exciting story about the client’s technology, business, and value proposition to educate potential investors.

The firm has a 60-plus-year history of representing trailblazers in the life sciences industry—from the earliest innovators to those that are shaping the future of healthcare today. We work closely with entrepreneurs, scientists, and investors who trust Wilson Sonsini’s strategic advice to establish and realize their companies’ business objectives. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships. We are often the company's only counsel and provide broad strategic advice with support from our cross-functional, global life sciences teams. This breadth of experience informs our IPO-related scientific writing and allows us to produce optimal capitalization results for our clients.

Wilson Sonsini’s IPO scientific writers are professionals in global patent portfolio development and management. They include former senior technology licensing executives at top-tier research universities and former in-house legal counsel for major life sciences companies.

The unparalleled combination of our scientific backgrounds and industry experience enables us to accelerate and streamline the IPO process by producing a business description in advance of an IPO organizational meeting, thereby allowing management to maintain its focus on operating the business.

Technical Writing and IPO Documentation

Wilson Sonsini Life Sciences: Technical Writing and IPO Documentation

Wilson Sonsini offers a suite of services for life sciences clients navigating the complexities of initial public offerings (IPOs). Leveraging the scientific expertise of the firm’s Patents and Innovations and Corporate practices, our team provides specialized business and technical writing services, including drafting the business section of the registration statement, preparing investor presentations, and handling other technical writing needed during the IPO process.

Uniquely, our life sciences-focused patent team consists of more than 170 legal professionals with Ph.D.s and other advanced degrees in biology, chemistry, biomedical sciences, or engineering. Our technical writing expertise encompasses biopharmaceuticals, small molecule therapeutics, research tools, medical devices, genomics, bioinformatics, artificial intelligence, and materials. Because our professionals are credentialed scientists who are intimately familiar with the science at the core of the client’s business, as scientific writers, they are well positioned to draft a Form S-1 or Form F-1 business section that meets the SEC’s exacting standards for registration statements, dovetails with the client’s patent strategy, and tells a compelling and exciting story about the client’s technology, business, and value proposition to educate potential investors.

The firm has a 60-plus-year history of representing trailblazers in the life sciences industry—from the earliest innovators to those that are shaping the future of healthcare today. We work closely with entrepreneurs, scientists, and investors who trust Wilson Sonsini’s strategic advice to establish and realize their companies’ business objectives. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships. We are often the company's only counsel and provide broad strategic advice with support from our cross-functional, global life sciences teams. This breadth of experience informs our IPO-related scientific writing and allows us to produce optimal capitalization results for our clients.

Wilson Sonsini’s IPO scientific writers are professionals in global patent portfolio development and management. They include former senior technology licensing executives at top-tier research universities and former in-house legal counsel for major life sciences companies.

The unparalleled combination of our scientific backgrounds and industry experience enables us to accelerate and streamline the IPO process by producing a business description in advance of an IPO organizational meeting, thereby allowing management to maintain its focus on operating the business.

Related Practices
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Finance and Structured Finance
  • Public Company Representation
  • Securities Litigation
  • Special Purpose Acquisition Companies (SPACs)
Recent Insights
Client Highlights
Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On Offering
On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.
Learn More
Alerts
SEC Proposes Significant Registered Offering Reforms to Increase Public Market Access
On May 19, 2026, the U.S. Securities and Exchange Commission (the SEC or Commission) announced proposed rule and form amendments that would substantially revise the framework for registered securities offerings by U.S. public companies. The proposal is intended to facilitate capital formation by broadening access to short-form registration, expanding offering communications flexibility, and reducing certain procedural burdens associated with registered offerings, while maintaining robust investor protections.
Learn More
View All
Recent Events
Affiliated Programs
NASDAQ Spring 2026 IPO Bootcamp
Join us for the second webinar in 2026 Bootcamp series. Hosted by Nasdaq Entrepreneurial Center, this half-day program is designed to help founders, CFOs, and executives be prepared for the complex journey of taking a company public. Speakers from Wilson Sonsini and KPMG will share actionable insights on IPO strategy that attract investors and ensure compliance, SEC regulations, financial reporting, and more.
Learn More
Affiliated Programs
Circle|Up New York
Wilson Sonsini will join The Circle, Hiive, and Gallagher for Circle|Up NY, an exclusive program for East Coast-based CFO|Circle members. Attendees will enjoy the fireside chat featuring Jeff Hoffmeister, Chief Financial Officer at Shopify and informal networking.
Learn More
View All
Newsletters
2024 Technology and Life Sciences PIPE and RDO Report
Dive into our comprehensive review of 205 PIPEs and RDOs by U.S. technology and life sciences firms for 2024. Following several years of low capital market activity, 2024 saw a significant increase compared to 2022 and 2023. However, ongoing volatility may lead companies to seek alternatives to traditional underwritten offerings for their financing needs.
Read the Report
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.